APA (7th ed.) Citation

T, S., T, K., N, M., K, S., T, T., Y, U., . . . H, M. (2025). Clinical outcomes of pembrolizumab plus chemotherapy for postoperative recurrent esophageal squamous cell carcinoma. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 38(3), . https://doi.org/10.1093/dote/doaf029

Chicago Style (17th ed.) Citation

T, Sugase, et al. "Clinical Outcomes of Pembrolizumab Plus Chemotherapy for Postoperative Recurrent Esophageal Squamous Cell Carcinoma." Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus 38, no. 3 (2025). https://doi.org/10.1093/dote/doaf029.

MLA (9th ed.) Citation

T, Sugase, et al. "Clinical Outcomes of Pembrolizumab Plus Chemotherapy for Postoperative Recurrent Esophageal Squamous Cell Carcinoma." Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus, vol. 38, no. 3, 2025, https://doi.org/10.1093/dote/doaf029.